|
gptkbp:instanceOf
|
gptkb:company
|
|
gptkbp:CEO
|
gptkb:John_Leonard
|
|
gptkbp:collaboratesWith
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:developedBy
|
ex vivo CRISPR therapies
in vivo CRISPR therapies
|
|
gptkbp:focusesOn
|
gene editing
|
|
gptkbp:foundedYear
|
2014
|
|
gptkbp:founder
|
gptkb:Jennifer_Doudna
gptkb:Nessan_Bermingham
|
|
gptkbp:fullName
|
gptkb:Intellia_Therapeutics,_Inc.
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NTLA
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:leadProductCandidate
|
gptkb:NTLA-2001
gptkb:NTLA-5001
gptkb:NTLA-6001
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:NTLA
|
|
gptkbp:technology
|
gptkb:CRISPR
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:NTLA
|
|
gptkbp:website
|
https://www.intelliatx.com/
|
|
gptkbp:bfsParent
|
gptkb:Intellia_Therapeutics
|
|
gptkbp:bfsLayer
|
5
|